LeMaitre Vascular (NASDAQ:LMAT) Issues FY24 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) updated its FY24 earnings guidance on Thursday. The company provided EPS guidance of $1.73-1.84 for the period, compared to the consensus EPS estimate of $1.65. The company issued revenue guidance of $212.7-217.3 million, compared to the consensus revenue estimate of $211.69 million. LeMaitre Vascular also updated its Q2 guidance to $0.45-0.50 EPS.

Analysts Set New Price Targets

A number of research firms have recently weighed in on LMAT. Stifel Nicolaus upgraded LeMaitre Vascular from a hold rating to a buy rating and increased their price target for the stock from $59.00 to $75.00 in a report on Friday, April 26th. KeyCorp initiated coverage on LeMaitre Vascular in a research note on Tuesday, February 6th. They set a sector weight rating on the stock. JMP Securities increased their target price on LeMaitre Vascular from $72.00 to $77.00 and gave the stock a market outperform rating in a research note on Friday. StockNews.com raised LeMaitre Vascular from a hold rating to a buy rating in a research note on Friday. Finally, Barrington Research increased their target price on LeMaitre Vascular from $69.00 to $79.00 and gave the stock an outperform rating in a research note on Friday. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, LeMaitre Vascular presently has a consensus rating of Moderate Buy and a consensus price target of $73.83.

LeMaitre Vascular Stock Up 11.2 %

NASDAQ:LMAT traded up $7.45 during trading hours on Friday, reaching $74.22. 329,984 shares of the stock were exchanged, compared to its average volume of 110,751. The stock has a market capitalization of $1.67 billion, a P/E ratio of 49.15, a P/E/G ratio of 3.20 and a beta of 0.88. LeMaitre Vascular has a 52 week low of $44.27 and a 52 week high of $74.64. The firm has a 50 day simple moving average of $65.93 and a 200-day simple moving average of $58.85.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.05. The business had revenue of $53.48 million for the quarter, compared to analysts’ expectations of $51.50 million. LeMaitre Vascular had a return on equity of 11.75% and a net margin of 16.99%. The company’s quarterly revenue was up 13.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.27 EPS. As a group, analysts expect that LeMaitre Vascular will post 1.77 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, May 30th. Shareholders of record on Thursday, May 16th will be paid a $0.16 dividend. The ex-dividend date is Wednesday, May 15th. This represents a $0.64 dividend on an annualized basis and a yield of 0.86%. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 42.38%.

Insider Transactions at LeMaitre Vascular

In related news, Director Lawrence J. Jasinski sold 5,110 shares of the business’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total transaction of $344,925.00. Following the completion of the transaction, the director now owns 5,309 shares of the company’s stock, valued at approximately $358,357.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other LeMaitre Vascular news, Director Lawrence J. Jasinski sold 5,110 shares of the company’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total value of $344,925.00. Following the completion of the transaction, the director now owns 5,309 shares of the company’s stock, valued at approximately $358,357.50. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO George W. Lemaitre sold 36,600 shares of the stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $68.03, for a total value of $2,489,898.00. Following the completion of the transaction, the chief executive officer now directly owns 2,187,526 shares of the company’s stock, valued at $148,817,393.78. The disclosure for this sale can be found here. In the last quarter, insiders sold 114,036 shares of company stock worth $7,873,749. 10.79% of the stock is owned by corporate insiders.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.